Found 33 with Last Name = 'vieira da cruz' and Initial = 'a' 
Affinity DataKi: 3.10E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 3.40E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 6.40E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 7.60E+3nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 1.08E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 1.30E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 1.30E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 1.89E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataKi: 2.00E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 150nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 220nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 390nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 410nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 420nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 460nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 870nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 9.70E+3nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.16E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.52E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 2.46E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 2.95E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 2.96E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 3.16E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 3.29E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 3.72E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 4.03E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 4.50E+4nMAssay Description:The rhGAA enzyme sold under the name Myozyme® used comes from residues of perfusions of the recombinant enzyme used for treating, by enzyme therapy, ...More data for this Ligand-Target Pair
Affinity DataIC50: 4.91E+4nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 1.04E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 1.82E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 2.97E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 3.41E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
Affinity DataIC50: 3.87E+5nMAssay Description:The inhibiting activity on recombinant human acid α-glucosidase (rhGAA) of the compounds is implemented using the Fluopol-ABPP method (Fluoresce...More data for this Ligand-Target Pair
